Vendor Landscape

The structural picture

Veterinary AI vendors in 2026 fall into three structural categories: integrated diagnostic giants (IDEXX, Zoetis, Antech/Mars) that own hardware, reagent supply chains, reference labs, and are adding AI as a layer on existing installed bases; AI-native radiology platforms (SignalPET, Vetology, Radimal) that entered through imaging and are mostly independent of the PIMS/diagnostics giants; and documentation AI specialists (VetRec, CoVet, Provet Cloud, Instinct/ScribbleVet) competing primarily on scribe quality, PIMS integration depth, and clinical intelligence roadmap.

The most strategically consequential fact: Mars Petcare (through Mars Veterinary Health, Banfield, VCA, Antech, and the Biobank) is building the most vertically integrated AI data position in the industry — owning genomics data, longitudinal clinical records from thousands of US clinics, reference lab infrastructure, and pharmaceutical research. No other player has equivalent breadth. IDEXX is the closest comparable in diagnostic hardware/software integration but does not own clinic networks or a biobank.

Major Player Profiles

IDEXX Laboratories

IDEXX is the world's largest veterinary diagnostics company. Its AI footprint spans in-clinic analyzers (SediVue Dx for urine sediment, inVue Dx for cytology and blood morphology) and cloud-based clinical pathology AI. The Cancer Dx panel — canine lymphoma detection launched in 2025, mast cell tumor expanding mid-2026 — represents IDEXX's push into AI-guided oncology diagnostics. IDEXX placed 1,900+ inVue Dx units in Q4 2025 alone, targeting 5,500 for full-year 2026. Its cloud-native PIMS is growing rapidly and is the future integration layer for AI across diagnostics, imaging, and clinical decision support.

Strategic position: dominant in lab hardware and reagents; now actively building AI around existing installed base. AI is a retention and upsell mechanism, not a standalone business. No native AI scribe. FNA cytology (highest-value GP cytology use) is "upcoming" for inVue Dx — a notable gap.

Zoetis

Zoetis holds the broadest single-instrument AI coverage via the Vetscan Imagyst — seven AI modules on one platform. The June 2025 launch of AI Masses (lymph node and skin lesion cytology) extends Imagyst into cytopathology. Zoetis is primarily a pharmaceutical and diagnostics company; its AI is concentrated in point-of-care instruments rather than PIMS or documentation. No radiology AI offering. No scribe product. Strongest position in fecal parasitology (peer-reviewed validated) and dermatology cytology (ear, skin swabs).

Mars Veterinary Health / Antech

Antech, the diagnostics arm of Mars Petcare, operates RapidRead and RapidRead Dental for radiology AI, building on Microsoft Azure AI with Mistral models. Mars also owns Banfield Pet Hospital, VCA, BluePearl (specialty and emergency), and the Petcare Biobank. The Mars ecosystem is uniquely positioned for longitudinal data collection across species, genomics, and clinical pathology — a data moat that will compound as AI training increasingly requires large proprietary datasets.^[1] Limitation: Mars AI is primarily distributed through the Antech account system and not directly sold to independent practices.

SignalPET

SignalPET is the most widely deployed independent veterinary radiology AI: 2,500+ clinics, 20M+ images, 63+ pathologies, 50+ countries. Its PACS-agnostic approach and under-10-minute setup made it the low-friction choice for rapid adoption. SignalSTAT (early 2024) added a 45-minute board-certified radiologist confirmation layer over the AI, offering a hybrid path between full AI primary read and pure teleradiology. IVC Evidensia (world's second-largest vet group) is rolling SignalPET across European and Canadian practices.

Risk: Published methodological concerns about independent validation remain unaddressed publicly. ACVR/ECVDI's statement that no commercial imaging AI meets required validation standards applies directly to SignalPET's tier-1 Immediate Report product.

Vetology

Vetology differentiates on transparency — publishing condition-specific validation data (heart failure: 89.5% sensitivity over 10,951 cases) — and on distribution through Patterson Veterinary. The 2025 ScribbleVet integration (one-click radiology order from within the scribe workflow) is a signal of future cross-category integration. Smaller clinic footprint than SignalPET; canine/feline only.

Radimal

Radimal combines free PACS with AI triage and specialist teleradiology, targeting referral and specialty settings. Cornell University named it preferred imaging provider in October 2025. Covers X-ray, ultrasound, CT, and MRI — the broadest modality coverage of the imaging AI platforms, though the AI component is primarily X-ray.

The Scribe Ecosystem

The documentation AI market is the most competitive segment, with five or more well-funded standalone vendors plus PIMS-native features from every major system. Competitive differentiation is currently based on: accuracy (the decisive variable, still self-reported), PIMS integration depth, specialty template coverage, and pricing. The market is consolidating via PIMS acquisition — Instinct Science's acquisition of ScribbleVet (January 2026) is the clearest signal. Expect further M&A as PIMS vendors acquire scribe technology rather than build it.

Key standalone scribes by positioning:

• VetRec: broadest PIMS coverage, largest enterprise customer base, academic partnerships (Cornell, Texas A&M)
• CoVet: copilot positioning with diagnostic suggestion layer; fastest recent growth (550% in 2025)
• Talkatoo: oldest dictation-first platform, largest installed base among dictation-mode tools, Patterson distribution
• Scribenote: free-tier entry point, solo practitioner focus
• ScribbleVet (Instinct): intelligence-native PIMS ambition, Plumb's integration, vet school adoption

Vendor Comparison Table

Competitive dynamics to watch

• PIMS integration as moat: Vendors who achieve deep native PIMS integration lock out competitors. Expect PIMS vendors to acquire scribe startups rather than build, and diagnostic vendors to acquire or partner with PIMS vendors to create integrated workflows.
• Mars data advantage compounding: The Biobank's longitudinal multi-omics dataset will generate AI training advantages that independent vendors cannot replicate without equivalent data access. The gap between Mars-network AI and independent vendor AI will likely widen through the decade.
• Validation as competitive differentiator: As ACVR/ECVDI pressure and potential AAVSB standards develop, published validation data will matter more. Vetology's transparency is currently undervalued by the market; it may become a differentiator if procurement standards tighten.
• International platforms: Provet Cloud (European) and Vet-AI/Joii (UK) demonstrate that non-US vendors are building strong AI positions, particularly in markets where regulatory frameworks (EU AI Act, RCVS) are clearer than in the US.